Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. We are called Strongbridge for a reason. Our name reflects the collective strength of our rare disease expertise, our product portfolio and pipeline, and our patient-driven culture—one that is fueled by performance, precision and heart. Together, we are working to remove the barriers and isolation associated with rare neuromuscular and endocrine diseases in order to connect patients with the life-enhancing treatment options they deserve. Strongbridge is incorporated in Ireland, and its U.S. headquarters are located just outside of Philadelphia, PA. Strongbridge Biopharma is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP. Rare Focus. Rare Commitment. Rare Passion. That’s Strongbridge.